Biotechnology
Compare Stocks
5 / 10Stock Comparison
ARMP vs INNV vs ALHC vs PHGE vs CNC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Healthcare Plans
Biotechnology
Medical - Healthcare Plans
ARMP vs INNV vs ALHC vs PHGE vs CNC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Medical - Care Facilities | Medical - Healthcare Plans | Biotechnology | Medical - Healthcare Plans |
| Market Cap | $304M | $1.03B | $3.66B | $1.02B | $27.63B |
| Revenue (TTM) | $5M | $946M | $4.26B | $0.00 | $198.10B |
| Net Income (TTM) | $-174M | $-22M | $20M | $-36M | $-6.44B |
| Gross Margin | 68.8% | 14.8% | 9.0% | — | 14.9% |
| Operating Margin | -6.4% | 1.5% | 0.8% | — | -3.7% |
| Forward P/E | — | 36.8x | 101.8x | — | 16.4x |
| Total Debt | $288M | $101M | $338M | $1M | $18.78B |
| Cash & Equiv. | $9M | $64M | $578M | $5M | $17.89B |
ARMP vs INNV vs ALHC vs PHGE vs CNC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Armata Pharmaceutic… (ARMP) | 100 | 173.6 | +73.6% |
| InnovAge Holding Co… (INNV) | 100 | 29.4 | -70.6% |
| Alignment Healthcar… (ALHC) | 100 | 81.8 | -18.2% |
| BiomX Inc. (PHGE) | 100 | 0.0 | -100.0% |
| Centene Corporation (CNC) | 100 | 87.6 | -12.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARMP vs INNV vs ALHC vs PHGE vs CNC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ARMP ranks third and is worth considering specifically for momentum.
- +5.1% vs PHGE's -94.1%
INNV lags the leaders in this set but could rank higher in a more targeted comparison.
ALHC carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 46.1%, EPS growth 99.4%, 3Y rev CAGR 40.2%
- 46.1% revenue growth vs PHGE's -62.3%
- 0.5% margin vs ARMP's -35.4%
- 1.8% ROA vs ARMP's -207.9%
Among these 5 stocks, PHGE doesn't own a clear edge in any measured category.
CNC is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 1 yrs, beta 0.41
- 84.5% 10Y total return vs ALHC's 3.6%
- Lower volatility, beta 0.41, Low D/E 93.6%, current ratio 1.68x
- Beta 0.41, current ratio 1.68x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 46.1% revenue growth vs PHGE's -62.3% | |
| Value | Better valuation composite | |
| Quality / Margins | 0.5% margin vs ARMP's -35.4% | |
| Stability / Safety | Beta 0.41 vs INNV's 1.49 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +5.1% vs PHGE's -94.1% | |
| Efficiency (ROA) | 1.8% ROA vs ARMP's -207.9% |
ARMP vs INNV vs ALHC vs PHGE vs CNC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
ARMP vs INNV vs ALHC vs PHGE vs CNC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CNC leads in 3 of 6 categories
ALHC leads 2 • ARMP leads 1 • INNV leads 0 • PHGE leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALHC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CNC and PHGE operate at a comparable scale, with $198.1B and $0 in trailing revenue. ALHC is the more profitable business, keeping 0.5% of every revenue dollar as net income compared to ARMP's -35.4%. On growth, ALHC holds the edge at +33.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $5M | $946M | $4.3B | $0 | $198.1B |
| EBITDAEarnings before interest/tax | -$30M | $4M | $66M | -$28M | -$5.9B |
| Net IncomeAfter-tax profit | -$174M | -$22M | $20M | -$36M | -$6.4B |
| Free Cash FlowCash after capex | -$26M | $39M | $237M | -$26M | $6.3B |
| Gross MarginGross profit ÷ Revenue | +68.8% | +14.8% | +9.0% | — | +14.9% |
| Operating MarginEBIT ÷ Revenue | -6.4% | +1.5% | +0.8% | — | -3.7% |
| Net MarginNet income ÷ Revenue | -35.4% | -2.3% | +0.5% | — | -3.3% |
| FCF MarginFCF ÷ Revenue | -5.4% | +4.1% | +5.6% | — | +3.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -12.1% | +15.5% | +33.3% | — | +7.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -79.0% | -161.3% | +2.1% | +17.1% | +18.3% |
Valuation Metrics
CNC leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $304M | $1.0B | $3.7B | $1.0B | $27.6B |
| Enterprise ValueMkt cap + debt − cash | $583M | $1.1B | $3.4B | $1.0B | $28.5B |
| Trailing P/EPrice ÷ TTM EPS | -1.73x | -34.41x | -4845.95x | -0.03x | -4.11x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 36.80x | 101.82x | — | 16.37x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 75.68x | — | — |
| Price / SalesMarket cap ÷ Revenue | 62.00x | 1.20x | 0.93x | — | 0.14x |
| Price / BookPrice ÷ Book value/share | — | 3.90x | 19.80x | — | 1.37x |
| Price / FCFMarket cap ÷ FCF | — | 38.61x | 32.37x | — | 6.39x |
Profitability & Efficiency
ALHC leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ALHC delivers a 11.5% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-3 for PHGE. INNV carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALHC's 1.89x. On the Piotroski fundamental quality scale (0–9), INNV scores 6/9 vs PHGE's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -8.2% | +11.5% | -2.7% | -28.6% |
| ROA (TTM)Return on assets | -2.1% | -4.1% | +1.8% | -80.4% | -7.9% |
| ROICReturn on invested capital | -36.0% | -6.8% | — | -4.4% | -21.6% |
| ROCEReturn on capital employed | -58.8% | -7.1% | +2.9% | -66.6% | -14.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 6 | 2 | 6 |
| Debt / EquityFinancial leverage | — | 0.38x | 1.89x | — | 0.94x |
| Net DebtTotal debt minus cash | $279M | $37M | -$240M | -$4M | $889M |
| Cash & Equiv.Liquid assets | $9M | $64M | $578M | $5M | $17.9B |
| Total DebtShort + long-term debt | $288M | $101M | $338M | $1M | $18.8B |
| Interest CoverageEBIT ÷ Interest expense | -1.88x | 5.96x | 1.27x | -33.64x | -9.03x |
Total Returns (Dividends Reinvested)
ARMP leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARMP five years ago would be worth $20,244 today (with dividends reinvested), compared to $6 for PHGE. Over the past 12 months, ARMP leads with a +510.3% total return vs PHGE's -94.1%. The 3-year compound annual growth rate (CAGR) favors ARMP at 83.7% vs PHGE's -77.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +26.5% | +45.9% | -11.3% | -70.7% | +33.9% |
| 1-Year ReturnPast 12 months | +510.3% | +112.0% | +16.3% | -94.1% | -10.3% |
| 3-Year ReturnCumulative with dividends | +519.4% | +16.6% | +148.0% | -98.8% | -18.0% |
| 5-Year ReturnCumulative with dividends | +102.4% | -70.3% | -16.6% | -99.9% | -19.6% |
| 10-Year ReturnCumulative with dividends | -97.6% | -68.7% | +3.6% | -100.0% | +84.5% |
| CAGR (3Y)Annualised 3-year return | +83.7% | +5.3% | +35.4% | -77.3% | -6.4% |
Risk & Volatility
CNC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CNC is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than INNV's 1.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CNC currently trades 87.2% from its 52-week high vs PHGE's 4.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.49x | 0.81x | 1.05x | 0.41x |
| 52-Week HighHighest price in past year | $16.34 | $10.68 | $23.87 | $14.71 | $64.15 |
| 52-Week LowLowest price in past year | $1.17 | $3.13 | $11.63 | $0.59 | $25.08 |
| % of 52W HighCurrent price vs 52-week peak | +50.8% | +70.9% | +75.1% | +4.3% | +87.2% |
| RSI (14)Momentum oscillator 0–100 | 42.0 | 49.8 | 38.1 | 21.2 | 81.6 |
| Avg Volume (50D)Average daily shares traded | 50K | 291K | 3.6M | 195K | 5.8M |
Analyst Outlook
CNC leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ARMP as "Buy", INNV as "Hold", ALHC as "Buy", PHGE as "Buy", CNC as "Buy". Consensus price targets imply 5960.6% upside for PHGE (target: $38) vs -10.2% for INNV (target: $7).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $15.00 | $6.80 | $24.83 | $38.00 | $51.00 |
| # AnalystsCovering analysts | 4 | 8 | 16 | 5 | 43 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.7% | 0.0% | 0.0% | +1.7% |
CNC leads in 3 of 6 categories (Valuation Metrics, Risk & Volatility). ALHC leads in 2 (Income & Cash Flow, Profitability & Efficiency).
ARMP vs INNV vs ALHC vs PHGE vs CNC: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ARMP or INNV or ALHC or PHGE or CNC a better buy right now?
For growth investors, Alignment Healthcare, Inc.
(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus -5. 2% for Armata Pharmaceuticals, Inc. (ARMP). Analysts rate Armata Pharmaceuticals, Inc. (ARMP) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ARMP or INNV or ALHC or PHGE or CNC?
Over the past 5 years, Armata Pharmaceuticals, Inc.
(ARMP) delivered a total return of +102. 4%, compared to -99. 9% for BiomX Inc. (PHGE). Over 10 years, the gap is even starker: CNC returned +84. 5% versus PHGE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ARMP or INNV or ALHC or PHGE or CNC?
By beta (market sensitivity over 5 years), Centene Corporation (CNC) is the lower-risk stock at 0.
41β versus InnovAge Holding Corp. 's 1. 49β — meaning INNV is approximately 262% more volatile than CNC relative to the S&P 500. On balance sheet safety, InnovAge Holding Corp. (INNV) carries a lower debt/equity ratio of 38% versus 189% for Alignment Healthcare, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ARMP or INNV or ALHC or PHGE or CNC?
By revenue growth (latest reported year), Alignment Healthcare, Inc.
(ALHC) is pulling ahead at 46. 1% versus -5. 2% for Armata Pharmaceuticals, Inc. (ARMP). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -817. 6% for Armata Pharmaceuticals, Inc.. Over a 3-year CAGR, ALHC leads at 40. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ARMP or INNV or ALHC or PHGE or CNC?
BiomX Inc.
(PHGE) is the more profitable company, earning 0. 0% net margin versus -35. 4% for Armata Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALHC leads at 0. 4% versus -636. 7% for ARMP. At the gross margin level — before operating expenses — ARMP leads at 68. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ARMP or INNV or ALHC or PHGE or CNC more undervalued right now?
On forward earnings alone, Centene Corporation (CNC) trades at 16.
4x forward P/E versus 101. 8x for Alignment Healthcare, Inc. — 85. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PHGE: 5960. 6% to $38. 00.
07Which pays a better dividend — ARMP or INNV or ALHC or PHGE or CNC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ARMP or INNV or ALHC or PHGE or CNC better for a retirement portfolio?
For long-horizon retirement investors, Centene Corporation (CNC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
41)). Both have compounded well over 10 years (CNC: +84. 5%, INNV: -68. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ARMP and INNV and ALHC and PHGE and CNC?
Both stocks operate in the null sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ARMP is a small-cap quality compounder stock; INNV is a small-cap quality compounder stock; ALHC is a small-cap high-growth stock; PHGE is a small-cap quality compounder stock; CNC is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.